secwatch.observer — SEC 8-K summary
======================================

Issuer:     AXIM BIOTECHNOLOGIES, INC. (AXIM)
CIK:        0001514946
Form:       8-K
Filed at:   2023-05-25T23:59:59+00:00
Accession:  0001096906-23-001188
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AXIM Biotechnologies appoints Kurt Phinney as COO; grants option for 2M shares
------------------------------------------------------------------------------

- Kurt Phinney appointed COO effective May 23, 2023; minimum six-month term.
- Compensation: option to buy up to 2,000,000 shares (S-8), vesting 1/6 every 30 days.
- Phinney's prior roles include VP Ops at Lumos Diagnostics and Versea Health.
- Consulting agreement with Accalle, LLC (Phinney's entity); no cash salary.
- Agreement may be terminated after initial term with 30 days' notice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1514946/000109690623001188/0001096906-23-001188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1514946/000109690623001188/axim-20230523.htm
  HTML page:      https://secwatch.observer/filing/0001096906-23-001188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer